naveglitazar and Disease-Models--Animal

naveglitazar has been researched along with Disease-Models--Animal* in 1 studies

Other Studies

1 other study(ies) available for naveglitazar and Disease-Models--Animal

Article	Year
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. Bioorganic & medicinal chemistry letters, 2005, Jan-03, Volume: 15, Issue:1 Herein we describe a series of potent and selective PPARgamma agonists with moderate PPARalpha affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes. Topics: Animals; Blood Glucose; Cinnamates; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Zucker; Structure-Activity Relationship; Triglycerides	2005

Article

Year

2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.

Bioorganic & medicinal chemistry letters, 2005, Jan-03, Volume: 15, Issue:1

Herein we describe a series of potent and selective PPARgamma agonists with moderate PPARalpha affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes.

Topics: Animals; Blood Glucose; Cinnamates; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Zucker; Structure-Activity Relationship; Triglycerides

2005